Daglif 5 & Daglif 10 5 mg/ 10 mg Tablet
PDF Leaflet Revision Date: 03/08/2022
Clinical Summary
Quick overview from the medicine insert
Indication
Improves glycaemic control in adults with type 2 diabetes mellitus.
Dosage (summary)
10 mg once daily for adults; no adjustment for mild renal impairment.
Special Populations
- Renal impairment
- Hepatic impairment
- Elderly
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding.
Key Drug Interactions
- Insulin
- Sulphonylureas
- Diuretics
Contraindications
- Hypersensitivity to dapagliflozin
- Moderate to severe renal impairment
- Type 1 diabetes
- Pregnancy
- Breastfeeding
Common side effects
- Genital infections
- Urinary tract infections
- Dizziness
Counselling Points
- Monitor for signs of ketoacidosis
- Stay hydrated
- Report genital infections promptly
Serious warnings
- Risk of metabolic acidosis
- Risk of diabetic ketoacidosis
- Risk of Fournier's gangrene
Important Disclaimer
The Daglif 5 & Daglif 10 5 mg/ 10 mg Tablet professional information leaflet below is the property of Zydus Healthcare Sa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
